- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.03. | BIOSERGEN AB: Biosergen scales up for future wins | 3 | Cision News | ||
| 05.03. | BIOSERGEN AB: Biosergen publishes interim report for fourth quarter 2024 | 2 | Cision News | ||
| 07.02. | BIOSERGEN AB: Biosergen's CEO: "These findings open up new possibilities" | 3 | Cision News | ||
| 04.02. | BIOSERGEN AB: Biosergen Successfully Completes Second Cohort of BSG005 Clinical Trial, Gaining Conclusive Proof-of-Concept Data, and Confirms 2025 Objectives | 1 | Cision News | ||
| 20.12.24 | BIOSERGEN AB: Biosergen Agrees to Accelerated Dosing Escalation in Ongoing Second Cohort of Clinical Trial | 4 | Cision News | ||
| 05.12.24 | BIOSERGEN AB: Biosergen resolves on a compensation issue to underwriters in connection with the completed exercise period for warrants of series TO3 | 2 | Cision News | ||
| 03.12.24 | Biosergen AB conducts a directed share issue to underwriters in connection with the completed exercise period for warrants of series TO3 | 1 | Cision News | ||
| BIOSERGEN Aktie jetzt für 0€ handeln | |||||
| 03.12.24 | Biosergen AB receives approximately SEK 44.9 million through warrants of series TO3 | 1 | Cision News | ||
| 26.11.24 | BIOSERGEN AB: Biosergen Doses First Patients in Second Cohort of BSG005 Clinical Trial for Life-Threatening Fungal Infections | 1 | Cision News | ||
| 26.11.24 | The last day of trading with the warrants of series TO3 in Biosergen AB is today, November 26, 2024 | 1 | Cision News | ||
| 21.11.24 | BIOSERGEN AB: Biosergen Releases Interview with Principal Investigator Dr. Pawan Singh on Drug-Resistant Fungal Infections and BSG005 | 1 | Cision News | ||
| 18.11.24 | BIOSERGEN AB: Biosergen has secured 100 percent of the warrants of series TO3 approximately SEK 44.9 million | 1 | Cision News | ||
| 18.11.24 | The exercise price for the warrants of series TO3 in Biosergen AB has been determined to SEK 0.49 | 1 | Cision News | ||
| 13.11.24 | BIOSERGEN AB: Biosergen discusses positive results in patients with deadly fungal infections | 2 | Cision News | ||
| 08.11.24 | Biosergen AB: Biosergen publishes interim report for third quarter 2024 | 103 | GlobeNewswire (Europe) | Friday November 8, 2024: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the third quarter 2024. The interim report is available as an attached document and on the... ► Artikel lesen | |
| 07.11.24 | BIOSERGEN AB: Biosergen Announces Safety Committee Approval to Proceed with Dose Escalation in Second Cohort for BSG005 Clinical Trial | 1 | Cision News | ||
| 06.11.24 | BIOSERGEN AB: Biosergen's CEO: "I'm optimistic that we may cure patients" | 2 | Cision News | ||
| 31.10.24 | BIOSERGEN AB: Biosergen Completes First Cohort of BSG005 Clinical Trial, Shows Promising Potential in Drug-Resistant Fungal Infections | 1 | Cision News | ||
| 18.10.24 | BIOSERGEN AB: Biosergen advances BSG005 antifungal drug candidate trial | 1 | Cision News | ||
| 07.10.24 | Biosergen AB: Biosergen Completes Enrollment of First Cohort in BSG005 Proof-of-Concept Trial | 121 | GlobeNewswire (Europe) | October 7, 2024 - Biosergen AB ("Biosergen"), a clinical-stage biotechnology company developing therapies for life-threatening fungal diseases, today announced the successful enrollment of the first... ► Artikel lesen |
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,135 | +1,25 % | Biotech Report: Sektor unter Druck - Evotec verlieren, Qiagen behauptet | (shareribs.com) Frankfurt / New York 26.03.2025 - Biotechwerte tendierten im deutschen Handel schwächer, lediglich 4SC konnte leichte Kursgewinne verbuchen. An der Wall Street rutschte der Sektor ab.... ► Artikel lesen | |
| TEMPUS AI | 46,695 | -3,20 % | Tempus AI Surges 43% YTD: Is it the Right Time to Invest in the Stock? | ||
| BIOAFFINITY TECHNOLOGIES | 1,050 | +281,82 % | RedChip Companies, Inc.: bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | ORLANDO, FLORIDA / ACCESS Newswire / March 28, 2025 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (Nasdaq:BIAF) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 13,940 | -12,38 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's ... | - Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile... ► Artikel lesen | |
| EVOTEC | 6,125 | +1,07 % | Evotec, NetraMark, Novo Nordisk - vom Labor zur goldenen digitalen Zukunft mit Künstlicher Intelligenz | Die Pharmabranche erlebt eine Revolution, die alles verändert! Künstliche Intelligenz jagt durch die Labore und schneidet alte Zöpfe ab. Algorithmen durchforsten Milliarden chemischer Strukturen in... ► Artikel lesen | |
| BIONTECH | 84,90 | +2,97 % | DEUTSCHE BANK RESEARCH stuft Biontech auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Biontech auf "Buy" mit einem Kursziel von 140 US-Dollar belassen. Analyst Emmanuel Papadakis befasste sich in einer am Mittwoch... ► Artikel lesen | |
| BEAM THERAPEUTICS | 17,610 | -9,90 % | Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration | U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| BB BIOTECH | 31,900 | +0,31 % | BB Biotech Aktie: Gibt es jetzt Probleme? | Die BB Biotech AG kämpft aktuell mit einem erheblichen Wertverlust. Die Aktie notiert bei 31,85 CHF und hat innerhalb der letzten Woche einen Rückgang von 8,08% verzeichnet. Im Monatsvergleich fällt... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,065 | -4,16 % | Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today | ||
| SPRINGWORKS THERAPEUTICS | 41,490 | -6,02 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen | |
| IMMUNOVANT | 15,210 | -10,95 % | Immunovant Inc.: Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies | Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a... ► Artikel lesen | |
| NUVALENT | 68,80 | -2,93 % | Nuvalent-Entwicklungschefin verkauft Aktien im Wert von 292.468 US-Dollar | ||
| SUMMIT THERAPEUTICS | 18,750 | -2,82 % | Cantor Fitzgerald maintains Overweight on Summit Therapeutics shares | ||
| KYMERA THERAPEUTICS | 24,945 | -8,93 % | Kymera Therapeutics (NASDAQ:KYMR) Trading Down 6.2% - Should You Sell? | ||
| GUBRA | 63,00 | +12,90 % | Gubra-Aktie +15%: Zeit fürs Comeback! | Die Gubra-Aktie ist in den letzten vier Wochen unter massiven Verkaufsdruck geraten und hat über ein Drittel ihres Wertes eingebüßt. Doch am Dienstagmorgen sendet das Papier des dänischen Biopharmaunternehmens... ► Artikel lesen |
BIOSERGEN AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,029 Euro und damit -4,58 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOSERGEN AB finden Sie auf Wallstreet Online.
